Former Emisphere investors sue following sale to Novo Nordisk

The USD 1.8bn price does not reflect the value of Emisphere, according to former Emisphere shareholders, who have sued MHR Fund Management.

Photo: Novo Nordisk / PR

Last year, Novo Nordisk bought US company Emisphere Technologies for USD 1.8bn. Former investors in Emisphere are now suing the company's largest shareholder, MHR Fund Management, according to Fierce Pharma.

Iszo, a New York-based investment fund, accuses MHR of manipulating the Emisphere board to sell the company at an inconvenient time at an artifically low price.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs